EX-99.1(B)3 10 dex991b3.htm CONSOLIDATED STATEMENTS OF OPERATION Prepared by R.R. Donnelley Financial -- Consolidated Statements of Operation
Exhibit 99.1 (b) 3
 
TechRx Incorporated
 
Consolidated Statements of Operations
 
    
Eleven Months Ended May 31 2002
     
Year Ended June 30 2001
  
    
(Dollars in Thousands)
  
Revenues (including $996 and $1,020 in 2002 and 2001, respectively, from NDCHealth)
                  
Retail independent pharmacies
   
$
23,642
 
   
$
25,395
 
Retail chain pharmacies
   
 
8,453
 
   
 
9,272
 
Mail order and institutional pharmacies
   
 
6,607
 
   
 
6,925
 
Canadian pharmacies
   
 
2,738
 
   
 
3,461
 
    
  
Total revenues
   
 
41,440
 
   
 
45,053
 
Cost of revenues (including $4,811 and $6,850 in 2002 and 2001, respectively, from NDCHealth)
   
 
26,189
 
   
 
30,113
 
    
  
Gross profit
   
 
15,251
 
   
 
14,940
 
Operating expenses:
                  
Sales and marketing (including $5,500 and $6,000 in 2002 and 2001, respectively, to NDCHealth)
   
 
10,787
 
   
 
13,254
 
Software development
   
 
9,138
 
   
 
10,725
 
General and administrative
   
 
6,629
 
   
 
8,361
 
Restructuring charge
   
 
1,406
 
   
 
1,980
 
Impairment of assets
   
 
—  
 
   
 
7,102
 
    
  
Total operating expenses
   
 
27,960
 
   
 
41,422
 
    
  
Loss from operations
   
 
(12,709
)
   
 
(26,482
)
Other income (expense):
                  
Interest income
   
 
154
 
   
 
686
 
Interest expense (including $323 and $235 in 2002 and 2001, respectively, to NDCHealth)
   
 
(1,084
)
   
 
(581
)
Other expense
   
 
(125
)
   
 
(90
)
    
  
Total other (expense) income
   
 
(1,055
)
   
 
15
 
    
  
Loss before income tax expense
   
 
(13,764
)
   
 
(26,467
)
    
  
Income tax expense
   
 
—  
 
   
 
60
 
    
  
Net loss
   
$
(13,764
)
   
$
(26,527
)
    
  
 
See accompanying notes.